Last updated on April 2019

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Renal Failure | Multiple Myeloma
  • Age: Between 66 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age 66 years-old
  • Patients with symptomatic, measurable and newly diagnosed multiple myeloma associated:
  • Severe renal failure at the time of transplantation (creatinine clearance < 40 ml/min/1.73m, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration)
  • Partial response after induction treatment
  • For patients who undergo autologous transplantation, absence of known contraindication for transplantation
  • Absence of amylose
  • Patient affiliated to a social security regimen or beneficiary of the same
  • Signed written informed consent form

Exclusion Criteria:

  • Patient without at least a partial hematological response following the induction stage
  • Medical history of previous malignancy
  • Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent (art. L.1121-6, L.112-7, L.1211-8, L.1211-9)
  • Pregnant or breastfeeding woman
  • Declining participation

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.